Key facts
| Price (PPV) | 50.50 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | cyclophosphamide |
| Class | Antineoplastic agents |
| ATC code | L01AA01 |
| Manufacturer | NOVOPHARMA |
| Presentation | Flacon de 500 mg |
| Nature | Médicament |
| Hospital price | 31.50 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement adjuvant et en situation métastatique des adénocarcinomes mammaires. Traitement des cancers ovariens, des cancers bronchiques notamment à petites cellules, des séminomes et carcinomes embryonnaires testiculaires, des cancers de la vessie, des sarcomes, des neuroblastomes, des lymphomes malins hodgkiniens et non hodgkiniens, des myélomes multiples, des leucémies aiguës notamment lymphoïdes. A forte dose, conditionnement des allo- et autogreffes médullaires. A faible dose, traitement des polyarthrites rhumatoïdes, granulomatose de Wegener, de certaines formes sévères de lupus érythémateux aigus disséminés, de néphropathies auto-immunes cortico-résistantes.
Find an open pharmacy
On-call pharmacies near you
About Cyclomide Novopharma 500 mg
Cyclomide Novopharma 500 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by NOVOPHARMA and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Cyclomide Novopharma 500 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Cyclomide Novopharma 500 mg
Answers to common questions from Moroccan patients about this drug.